|
1
|
Baumunk D, Blana A, Ganzer R, Henkel T,
Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch
U, Köhrmann KU and Schostak M: Focal prostate cancer therapy:
Capabilities, limitations and prospects. Urologe A. Oct
18–2012.(Epub ahead of print) (In German).
|
|
2
|
Obertova Z, Brown C, Holmes M and
Lawrenson R: Prostate cancer incidence and mortality in rural men -
a systematic review of the literature. Rural Remote Health.
12:20392012.PubMed/NCBI
|
|
3
|
van der Meer S, Löwik SA, Hirdes WH,
Nijman RM, Van der Meer K, Hoekstra-Weebers JE and Blanker MH:
Prostate specific antigen testing policy worldwide varies greatly
and seems not to be in accordance with guidelines: a systematic
review. BMC Fam Pract. 13:1002012.
|
|
4
|
Cheng L, Montironi R, Bostwick DG,
Lopez-Beltran A and Berney DM: Staging of prostate cancer.
Histopathology. 60:87–117. 2012. View Article : Google Scholar
|
|
5
|
Provenzano M: New biomarkers in prostate
cancer. Praxis (Bern 1994). 101:115–121. 2012.(In German).
|
|
6
|
Ou YC, Chen JT, Cheng CL, Ho HC and Yang
CR: Radical prostatectomy for prostate cancer patients with
prostate-specific antigen >20 ng/ml. Jpn J Clin Oncol.
33:574–579. 2003. View Article : Google Scholar
|
|
7
|
Mener DJ: Prostate specific antigen
reduction following statin therapy: Mechanism of action and review
of the literature. IUBMB Life. 62:584–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roy M, Kung HJ and Ghosh PM: Statins and
prostate cancer: role of cholesterol inhibition vs. prevention of
small GTP-binding proteins. Am J Cancer Res. 1:542–561.
2011.PubMed/NCBI
|
|
9
|
Zhang Y, Ma B and Fan Q: Mechanisms of
breast cancer bone metastasis. Cancer Lett. 292:1–7. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karakiewicz PI and Hutterer GC: Predictive
models and prostate cancer. Nat Clin Pract Urol. 5:82–92. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karlou M, Tzelepi V and Efstathiou E:
Therapeutic targeting of the prostate cancer microenvironment. Nat
Rev Urol. 7:494–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khamis ZI, Iczkowski KA and Sang QX:
Metastasis suppressors in human benign prostate, intraepithelial
neoplasia, and invasive cancer: their prospects as therapeutic
agents. Med Res Rev. 32:1026–1077. 2012. View Article : Google Scholar
|
|
13
|
Minato N, Takada T, Koga M and Sugao H:
Prostate cancer with disseminated carcinomatosis of bone marrow
initially presenting with disseminated intravascular coagulation
syndrome: a case report. Hinyokika Kiyo. 58:249–253. 2012.(In
Japanese).
|
|
14
|
Payne H, Khan A, Chowdhury S and Davda R:
Hormone therapy for radiorecurrent prostate cancer. World J Urol.
Sep 21–2012.(Epub ahead of print).
|
|
15
|
Smith BN and Odero-Marah VA: The role of
Snail in prostate cancer. Cell Adh Migr. 6:433–441. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hour MJ, Tsai SC, Wu HC, Lin MW, Chung JG,
Wu JB, Chiang JH, Tsuzuki M and Yang JS: Antitumor effects of the
novel quinazolinone MJ-33: Inhibition of metastasis through the
MAPK, AKT, NF-κB and AP-1 signaling pathways in DU145 human
prostate cancer cells. Int J Oncol. Jul 18–2012.(Epub ahead of
print).
|
|
17
|
Lee KH, Choi EY, Hyun MS and Kim JR:
Involvement of MAPK pathway in hypoxia-induced up-regulation of
urokinase plasminogen activator receptor in a human prostatic
cancer cell line, PC3MLN4. Exp Mol Med. 36:57–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mulholland DJ, Kobayashi N, Ruscetti M,
Zhi A, Tran LM, Huang J, Gleave M and Wu H: Pten loss and RAS/MAPK
activation cooperate to promote EMT and metastasis initiated from
prostate cancer stem/progenitor cells. Cancer Res. 72:1878–1889.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo LW, Gao L, Rothschild J, Su B and
Gelman IH: Control of protein kinase C activity, phorbol
ester-induced cytoskeletal remodeling, and cell survival signals by
the scaffolding protein SSeCKS/GRAVIN/AKAP12. J Biol Chem.
286:38356–38366. 2011. View Article : Google Scholar
|
|
20
|
Marques RB, Dits NF, Erkens-Schulze S, van
Ijcken WF, van Weerden WM and Jenster G: Modulation of androgen
receptor signaling in hormonal therapy-resistant prostate cancer
cell lines. PLoS One. 6:e231442011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanoh Y, Ohtani H, Egawa S, Baba S and
Akahoshi T: Changes of proteases and proteinase inhibitors in
androgen-dependent advanced prostate cancer patients with
alpha2-macroglobulin deficiency. Clin Lab. 58:217–225. 2012.
|
|
22
|
Ramsay AK, McCracken SR, Soofi M, Fleming
J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR,
Nuttall RK, Seywright M, Marquez R, Keller E and Leung HY: ERK5
signalling in prostate cancer promotes an invasive phenotype. Br J
Cancer. 104:664–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou
HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9
via EGFR-MEK-ERK pathway activation to promote prostate cancer cell
invasion. Int J Oncol. 40:1714–1724. 2012.PubMed/NCBI
|
|
24
|
Low JA, Johnson MD, Bone EA and Dickson
RB: The matrix metalloproteinase inhibitor batimastat (BB-94)
retards human breast cancer solid tumor growth but not ascites
formation in nude mice. Clin Cancer Res. 2:1207–1214. 1996.
|
|
25
|
Wojtowicz-Praga SM, Dickson RB and Hawkins
MJ: Matrix metalloproteinase inhibitors. Invest New Drugs.
15:61–75. 1997. View Article : Google Scholar
|
|
26
|
Shinoda K, Shibuya M, Hibino S, Ono Y,
Matsuda K, Takemura A, Zou D, Kokubo Y, Takechi A and Kudoh S: A
novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor
growth, metastasis and angiogenesis by human fibrosarcoma cell
line. Int J Oncol. 22:281–288. 2003.PubMed/NCBI
|
|
27
|
Yu CC, Hsieh CR, Hsiao G, Chen PY, Chang
ML, Yin HW, Lee TH and Lee CK: Regulated expressions of MMP-2, -9
by diterpenoids from Euphorbia formosana Hayata. Molecules.
17:2082–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee MH, Yang HI, Lu SN, Jen CL, You SL,
Wang LY, Wang CH, Chen WJ and Chen CJ: Chronic hepatitis C virus
infection increases mortality from hepatic and extrahepatic
diseases: a community-based long-term prospective study.
R.E.V.E.A.L-HCV Study Group. J Infect Dis. 206:469–477. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu CC, Yang JS, Chiang JH, Hour MJ,
Amagaya S, Lu KW, Lin JP, Tang NY, Lee TH and Chung JG: Inhibition
of invasion and migration by newly synthesized quinazolinone MJ-29
in human oral cancer CAL 27 cells through suppression of MMP-2/9
expression and combined down-regulation of MAPK and AKT signaling.
Anticancer Res. 32:2895–2903. 2012.PubMed/NCBI
|
|
30
|
Chen YY, Chiang SY, Lin JG, Ma YS, Liao
CL, Weng SW, Lai TY and Chung JG: Emodin, aloe-emodin and rhein
inhibit migration and invasion in human tongue cancer SCC-4 cells
through the inhibition of gene expression of matrix
metalloproteinase-9. Int J Oncol. 36:1113–1120. 2010.PubMed/NCBI
|
|
31
|
Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY,
Yu CC and Chung JG: Butein inhibits the migration and invasion of
SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK,
JNK, p38, and uPA signaling multiple pathways. J Agric Food Chem.
59:9032–9038. 2011. View Article : Google Scholar
|
|
32
|
Hu WG, Li JW, Feng B, Beveridge M, Yue F,
Lu AG, Ma JJ, Wang ML, Guo Y, Jin XL and Zheng MH: Vascular
endothelial growth factors C and D represent novel prognostic
markers in colorectal carcinoma using quantitative image analysis.
Eur Surg Res. 39:229–238. 2007. View Article : Google Scholar
|
|
33
|
Ma D, Gerard RD, Li XY, Alizadeh H and
Niederkorn JY: Inhibition of metastasis of intraocular melanomas by
adenovirus-mediated gene transfer of plasminogen activator
inhibitor type 1 (PAI-1) in an athymic mouse model. Blood.
90:2738–2746. 1997.PubMed/NCBI
|
|
34
|
Maarouf A, Adham M, Scoazec JY and
Partensky C: Mixed hepato/cholangiocarcinoma with paraneoplastic
hypercalcemia. J Hepatobiliary Pancreat Surg. 15:224–227. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang D, Gu T, Wang T, Tang Q and Ma C:
Effects of osthole on migration and invasion in breast cancer
cells. Biosci Biotechnol Biochem. 74:1430–1434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin SS, Lai KC, Hsu SC, Yang JS, Kuo CL,
Lin JP, Ma YS, Wu CC and Chung JG: Curcumin inhibits the migration
and invasion of human A549 lung cancer cells through the inhibition
of matrix metalloproteinase-2 and -9 and Vascular Endothelial
Growth Factor (VEGF). Cancer Lett. 285:127–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu JW, Cai MX, Xin Y, Wu QS, Ma J, Yang
P, Xie HY and Huang DS: Parthenolide induces proliferation
inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp
Clin Cancer Res. 29:1082010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qin JM, Yin PH, Li Q, Sa ZQ, Sheng X, Yang
L, Huang T, Zhang M, Gao KP, Chen QH, Ma JW and Shen HB: Anti-tumor
effects of brucine immuno-nanoparticles on hepatocellular
carcinoma. Int J Nanomedicine. 7:369–379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Weigel MT, Kramer J, Schem C, Wenners A,
Alkatout I, Jonat W, Maass N and Mundhenke C: Differential
expression of MMP-2, MMP-9 and PCNA in endometriosis and
endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 160:74–78.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng W, Zhang Y, Ma D, Shi Y, Liu C and
Wang P: ()Equol inhibits invasion in prostate cancer DU145 cells
possibly via down-regulation of matrix metalloproteinase-9, matrix
metalloproteinase-2 and urokinase-type plasminogen activator by
antioxidant activity. J Clin Biochem Nutr. 51:61–67. 2012.
View Article : Google Scholar
|
|
41
|
Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai
KC, Ma CY, Wood WG and Chung JG: Berberine suppresses in vitro
migration and invasion of human SCC-4 tongue squamous cancer cells
through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and
-9. Cancer Lett. 279:155–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
